Sign in Sign up for free

Edesa Biotech Forward P/E

What is the Forward P/E of Edesa Biotech?

The Forward P/E of Edesa Biotech, Inc. is 0.17

What is the definition of Forward P/E?



Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Forward P/E of companies in the Health Care sector on NASDAQ compared to Edesa Biotech

What does Edesa Biotech do?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Companies with forward p/e similar to Edesa Biotech